Cardiovascular Systems (Nasdaq:CSII) announced today that it fully launched its 2.00 Max Crown for peripheral orbital atherectomy systems.
St. Paul, Minnesota–based Cardiovascular Systems built the 2.00 Max Crown on its Diamondback 360 orbital atherectomy platform. It features an increased 70-micron, diamond-coated crown.
According to a news release, the crown creates more efficient engagement in mixed plaque. This helps achieve an optimal luminal gain in mild to moderately calcified lesions above the knee.
Dr. Amit Srivastava of the Bay Area Heart Center in St. Petersburg, Florida, incorporated the 2.00 Max Crown into his practice. He said it “greatly expands” lesions treatable with Cardiovascular Systems’ orbital atherectomy system. He added that it “delivers exceptional luminal gain” for mixed morphology lesions above the knee.
“The full commercial launch of the 2.00 Max Crown represents another important product launch for CSI as we broaden and diversify our product offering,” said Scott Ward, chairperson and CEO of Cardiovascular Systems.
According to Cardiovascular Systems, peripheral artery disease (PAD) affects millions of American seniors. Plaque accumulates in peripheral arteries and reduces blood flow. The Mayo Clinic says that symptoms can include leg pain when walking or resting.
“Our peripheral orbital atherectomy systems can now treat a wider range of plaque morphologies throughout the leg. Combining this new device with our full line of interventional support devices, we continue to advance the ability of physicians to improve outcomes for patients undergoing peripheral interventions.”
